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Economic Analysis of Integrated Continuous and Batch
Pharmaceutical Manufacturing: A Case Study
Spencer D. Schaber,† Dimitrios I. Gerogiorgis,† Rohit Ramachandran,†,§ James M. B. Evans,‡
Paul I. Barton,† and Bernhardt L. Trout*,‡
†Process Systems Engineering Laboratory, Department of Chemical Engineering and ‡Department of Chemical Engineering,
Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
ABSTRACT: The capital, operating, and overall costs of a dedicated continuous manufacturing process to synthesize an active
pharmaceutical ingredient (API) and formulate it into tablets are estimated for a production scale of 2000 t of tablets per year, with
raw material cost, production yield, and API loading varied over broad ranges. Costs are compared to batch production in a
dedicated facility. Synthesis begins with a key organic intermediate three synthetic steps before the ﬁnal API; results are given for key
intermediate (KI) costs of $100 to $3000/kg, with drug loadings in the tablet of 10 and 50 wt %. The novel continuous process
described here is being developed by an interdisciplinary team of 20 researchers. Since yields are not yet well-known, and continuous
processes typically have better yields than batch ones, the overall yields of the continuous processes with recycling were set equal to
that of the batch process. Without recycling, yields are 10% lower, but less equipment is required. The continuous process has not
been built at large scale, so Wroth factors and other assumptions were used to estimate costs. Capital expenditures for continuous
production were estimated to be 20 to 76% lower, depending on the drug loading, KI cost, and process chosen; operating
expenditures were estimated to be between 40% lower and 9% higher. The novel continuous process with recycling coupled to a
novel direct tablet formation process yields the best overall cost savings in each drug loading/KI price scenario: estimated savings
range from 9 to 40%. Overall cost savings are also given assuming the yield in the continuous case is 10% above and 10% below that
of the batch process. Even when yields in the continuous case are lower than in the batch case, savings can still be achieved because
the labor, materials handling, CapEx, and other savings compensate.
’ INTRODUCTION
Continuous manufacturing (CM) is attracting increasing atten-
tion within the pharmaceutical industry today because it could lead
to signiﬁcant decreases in production costs while improving product
quality.1,2 Historically, production costs were seen as a small enough
part of the overall industry expenses thatmajor cost reductions were
not needed. Regulations also drove production toward the batch
mode, since processes were required to be run in exactly the same
way for the lifetime of the therapy. Also, batch production allows
veriﬁcation of quality of each batch from each process before further
processing, whereas a “batch” in a continuous process is not
contained in the same way.3,4 Today, however, it is becoming more
diﬃcult for pharmaceutical companies to meet proﬁt expectations,
due to increasing research and development (R&D) costs and
competition from generics manufacturers.5 At the same time,
regulatory bodies are shifting the emphasis toward process under-
standing and giving more freedom when such understanding is
demonstrated.6 For suﬃciently large production scales, continuous
processes tend to have lower production costs;CMwould also allow
manufacturers to use the increased process understanding for online
process control, yielding consistently high-quality product and less
material wasted as oﬀ-spec product.7,8
A review of the ﬁne and commodity chemical industries demon-
strates that CM could oﬀer both operating expenditure (OpEx) and
capital expenditure (CapEx) savings for the pharmaceutical indus-
try. Labor for transporting material between batch units, labor for
quality assurance/quality control (QA/QC), and in-process inven-
tory (working capital) can all be signiﬁcantly reduced in continuous
processing.1,9 Processing equipment for ﬁne chemical synthesis can
be made much smaller by moving to continuous processing, as well
has having larger surface area to volume ratios, which implies a safer
plant (a smaller holdup of solvents in reactors and enhanced heat
transfer for safe handling of highly exothermic reactions), a smaller
investment in reactors, and faster change over in multipurpose
plants.7,8,10More rapid mixing, reaction, and quenching are possible
in continuous ﬂow,11 enabling reactions that would produce
signiﬁcantly more impurities if run in batch mode, such as in the
ﬁrst reaction in the novel continuous process presented in this work.
Plant footprint can also be reduced due to smaller processing
equipment, with commensurate energy savings for heating, ventila-
tion, and air conditioning.12
Pharmaceutical processes often contain continuous or semi-
continuous processing steps, such as milling and tablet com-
pression, but the processes are started and stopped to mirror
the batch processing in other steps. These steps can be more
naturally run in a continuous manner, potentially yielding more
consistent product quality.1,4 Scaleup of batch granulation can be
diﬃcult, and is sometimes easier in continuous mode, so devel-
opment of a needed granulation process could begin on con-
tinuous equipment, easing scaleup for production.3 Recently, the
lack of continuous tablet coating equipment was a bottleneck for
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continuous pharmaceutical production,4 but now it is available.
Continuous powder mixing has been shown to perform as
needed, with excellent time stability.13
In addition to cost savings, developing continuous processes early
on, using microreactors for instance, can enhance process under-
standing early in the patent life of a product, easing scale-up and
leading to additional time during which the product can be sold
exclusively by the patent holder, aswell as the ability to bring therapies
to ailing people more quickly.1 Recent developments in process
analytical technology (PAT)will allowmanufacturers to complete the
shift to continuous manufacturing, as long as it proves cost-eﬀective.5
Despite studies on the individual diﬀerences between batch and
continuous processing,1,8,9,12 to date, an integrated analysis of the
continuous manufacture of a ﬁnal drug product from a late-stage
organic KI has not been published. The Novartis-MIT Center for
Continuous Manufacturing (CCM) is focused on a holistic ap-
proach where we consider manufacture of the ﬁnal drug product
from starting materials available as ﬁne chemicals. In this work we
estimate CapEx, OpEx, and present cost of a dedicated batch
process and four continuous processes that are enabled by new
technologies developed for continuous production. While many
pharmaceutical production processes use multipurpose equipment
to manufacture several drugs in partial-year campaigns, very high-
volume drugs are sometimes produced on dedicated equipment.
’PROCESS DESCRIPTION
For both the batch and continuous processes, the assessment
starts with a late-stage organic key intermediate (KI) molecule,
three synthetic steps before the ﬁnal active pharmaceutical
ingredient (API), and produces a ﬁnal drug product: tablets.
The production scale is 2000 t of tablets per year, which is on par
with the production scale of a very high-volume “blockbuster”
drug. API loadings in the tablet of 10 and 50 wt % were used to
account for variations in API potency. Both processes produce
the same drug product. The batch process has been extensively
developed by Novartis, whereas the continuous process is being
developed in the Center for Continuous Manufacturing.
Batch Process. The sequence of unit operations for the batch
process is given in Figure 1. The raw materials requirements and
costs for one scenario are given in Table 1 and Table 2. We are
not permitted to disclose further details of the process.
Figure 1. Process ﬂow diagram for batch (Bx) manufacturing route.
Table 1. Raw Materials Requirements for All Processes at 50 wt % API Loadinga.
materials Bx CM1R/DTF CM1/DTF CM1R/RC CM1/RC
organic reagents 1 955 000 1 597 000 3 112 000 1 597 000 3 112 000
inorganic reagents 5 508 000 3 659 000 3 659 000 3 659 000 3 659 000
organic solvents 34 090 000 24 659 000 29 497 000 24 659 000 29 497 000
water 22 907 000 7 803 000 9 965 000 7 803 000 9 965 000
excipients and coatings 1 004 000 1 000 000 1 000 000 1 000 000 1 000 000
total 65 464 000 38 718 000 47 233 000 38 718 000 47 233 000
aAll values in kg/year. DTF, direct tablet formation; RC, roller compaction.
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Novel CM Route (CM1). The CCM team developed a new
synthetic route (CM1; Figure 2) that utilizes pathways that are
not feasible in a batch process. For example, processing in a
continuous-flow reactor enables a muchmore rapid deprotection
reaction than batch reaction; translating the CM1 route into a
standard batch process would result in significant degradation of
the product because the required rate of reagent addition cannot
be achieved in batch mode. Also, the continuous processes save
an average of 61% of the annual water usage and 21 wt % of the
annual solvent usage compared to batch. Reactors 1, 2, and 3 are
plug-flow reactors. The crystallizer and combined reactor/crys-
tallizer are agitated tanks. The API synthesis is coupled with two
downstream process options: roller compaction (RC) and a
novel direct tablet formation (DTF) process. RC is a well-
established pharmaceutical technology; a patent application is
being prepared for the novel direct tablet formation process, so it
is not described in detail here. Since the yields for the final
continuous processes are not known precisely, yields have been
set such that the overall yield for the continuous process with
recycling for the first reaction (CM1R) is equal to that of the
batch process, and the overall yield of the continuous process
without recycling (CM1) is 10% below that of the batch process.
Overall cost savings are also given for the case where overall yield
for process CM1R is 10% below and 10% above that of the batch
case. In each case, the overall yield for process CM1 is 10% below
the corresponding overall yield for process CM1R. The actual
yields that have been demonstrated in bench-scale continuous
reactions are bracketed by these scenarios; it is believed that a
mature continuous process will have yields equal to or better than
the batch yields, since the continuous process already has
competitive yields despite being developed for fewer than half
as many years, at a much smaller scale, and by fewer people.
Continuous reactions scale up very predictably and in an
economically favorable way.8 One issue currently limiting the
savings is microreactor plugging or fouling, which can be
observed as an increasing pressure drop across the reactor.7,8
The methods for using microreactors with heterogeneous cata-
lysts or severe precipitation are not mature.7 However, several
workarounds to the plugging and fouling issue are possible, based
on including strategic solvent choice, ﬂow velocity, temperature,
and device geometry.7 Microreactors have been successfully used
to produce hundreds of kilograms of product in a few weeks.8
Novel CM Route with Recycle (CM1R). Process CM1R is
identical to CM1, except that a single recycle loop and appro-
priate separation equipment are added to increase the effective
yield (from 86.4% to 98.5%) in the first step (Reactor 1) of the
Figure 2. Process ﬂow diagram for continuous manufacturing route CM1, showing both options for forming tablets.
Table 2. Raw Materials Costs for All Processes at 50 wt % API Loading and $3000/kg KIa
materials Bx CM1R/DTF CM1/DTF CM1R/RC CM1/RC
organic reagents 3,394,145,000 3,375,898,000 3,899,888,000 3,375,898,000 3,899,888,000
inorganic reagents 2,674,000 4,784,000 4,784,000 4,784,000 4,784,000
organic solvents 92,356,000 22,864,000 27,263,000 22,864,000 27,263,000
water 2,182,000 780,000 996,000 780,000 996,000
excipients and coatings 15,936,000 15,893,000 15,893,000 15,893,000 15,893,000
total 3,507,293,000 3,420,219,000 3,948,824,000 3,420,219,000 3,948,824,000
aAll values in $/year. DTF, direct tablet formation; RC, roller compaction.
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API synthesis from the KI. Separation equipment and recycle are
essential in order to reduce formation of the primary impurity.
Without the separation step, the primary product of the reaction
can undergo a subsequent reaction to form an impurity. The
overall yields (mol drug substance/mol KI) of processes CM1 and
CM1R are 69% and 79%, respectively; that of the batch process is
79%. Even without recycling, significant savings overall are esti-
mated, due to savings in CapEx, working capital, quality
assurance and control, labor, materials handling, waste handling,
and utilities.
Material Balances. Material requirements and costs for all
processes are given in Table 1. For Table 2, the cost of the KI
(one of the organic reagents) is $3000 kg/year, whereas costs for
other raw materials are from vendor quotes, and are typically
much less than $3000/kg.
’COST ANALYSIS METHODS
Green-ﬁeld construction of a new, dedicated plantwas considered
in all cases. A 335-day working year was considered, with 30 days left
for maintenance, cleaning, and startup/shutdown. One production
line per plant was assumed. Batch process eﬀective utilization time
was assumed to be 85% for upstream processes and 55% for
downstream processes; 95% was assumed for all continuous pro-
cesses. This is the percentage of time when the process equipment is
actually processing material. The remaining time is spent ﬁlling,
emptying, and cleaning the batch processing unit, or simply waiting
for material to be processed. These assumptions are optimistic for
batch production, representing lean batch operations in dedicated
production: According to Vervaet and Remon,4 the overall equip-
ment eﬀectiveness (OEE), a related metric, takes a typical value in
batch pharmaceutical production of 30%, with good processes
having 74% and “best-in-class” production lines reaching 92%.
Capital Expenditures (CapEx). Equipment Size and Cost
Estimation. Vendor price quotations for all process equipment
were obtained for both batch and continuous equipment over a
wide range of sizes, and the smallest unit of sufficiently large size
was selected.When price quotations were only available for batch
equipment, a 10% price premium was assumed for continuous
units relative to a batch unit of the same size, to account for the
increased process engineering (CapEx) required to operate a
process continuously with feedback control, as compared to batch
processes which are typically operated in an open-loop manner.
Scaling of cost could be approximatedwell (R2g 0.98) by a power
law in the following cases: plug-flow reactor, exponent 0.42;
filtration equipment, exponent 0.33; agitated vessel/CSTR/crys-
tallizer, exponent 0.20; dryer, exponent 0.21.
Calculation of Overall CapEx from Individual Process Equip-
ment Costs. The total cost of processing equipment excluding
any ancillary equipment, delivery, electrical, engineering, or
piping expenses is termed the FOB (free on board) cost. From
delivered equipment cost (1.05  FOB cost), Wroth factors
(Table 3) were used to calculate delivered installed equipment
cost, which includes ancillary equipment, delivery, electrical,
engineering, and piping costs.14 Wroth factors allow quick
estimation of installation and other necessary equipment costs,
and are commonly used at this stage of an economic analysis.
ðdelivered installed equipment costÞ
¼ ðWroth factorÞ  ðdelivered equipment costÞ ð1Þ
Additional CapEx heuristics used in the present analysis are
summarized in Table 4. Since pharmaceutical production scales
are smaller than typical commodity chemical production scales,
and must adhere to stricter hygiene regulations, the additional
expenses are expected to comprise a larger fraction of the CapEx.
Thus, the values used were the upper bounds of the ranges given
by Couper et al.
Operating Expenditures (OpEx). Operating expenditures
were calculated for KI prices of $100, $500, and $3000/kg.
The heuristics used are summarized in Table 5. The continuous
plant has not been built at large scale, so the values for labor,
materials handling, and QA/QC savings represent our best
estimates at this time. For example, OpEx savings are expected
in QA/QC since some manual sampling and analysis can be
replaced by online analysis.
Table 3. Selected Wroth Factors14
unit Wroth factor
distillation tower and internals 4.0
instrument 4.1
process tank 4.1
reactor (factor into appropriate process
tanks and other equipment)
storage tank 3.5
all other equipment 3.5
Table 4. Summary of CapEx Heuristics Used
item cost
(1) FOB cost sum of processing equipment units14
(2) delivery 5% of FOB cost14
(3) installation: ancillary equipment,
automation, electrical, piping, and engineering
[(Wroth factor)  1]  (delivered equipment cost)14
(4) battery-limits installed cost (BLIC) sum of items (1) to (3)14
(5) buildings and structures 20% of BLIC14
(6) contingency 20% of BLIC14
(7) oﬀsite capital (for a grass-roots plant) 150% of BLIC14
(8) service facilities 20% of BLIC14
(9) waste disposal not included in CapEx; assumed to be treated at a nominal cost indicated in Table 5
(10) working capital 35% of annual sales14w used 35% of annual materials costs for batch; 3.5% for continuous,
since throughput times are expected to be 10x lower in continuous processing
(11) total CapEx sum of items (4) to (10)
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Overall Cost of Production. To quantify overall cost
differences accounting for both CapEx and OpEx, present
cost of the project (eq 2) was calculated for each processing
option. This is the discounted total cost of the project,
excluding any revenue. Present cost of the project is similar
to net present value (NPV, eq 3), but does not include
revenue. This figure of merit was chosen because we are
comparing costs, not NPV.
ðpresent costÞ ¼ ðCapExÞ þ ∑
τ
i¼ 1
ðOpExÞ
ð1 þ rdÞi
ð2Þ
ðNPVÞ ¼  ðCapExÞ
þ ∑
τ
i¼ 1
ðOpExÞ
ð1 þ rdÞi
þ ðrevenueÞð1 þ rdÞi
( )
ð3Þ
Discount rate (rd) was 7%, construction period was 1 year,
and project lifetime (τ) was 15 years.
Contributors to Overall Cost Savings. To quantify the
contributions of different expenses to the cost differences for
CM relative to batch, the following quantity was defined:
ðcontribution to present cost differenceÞ
¼ ð present cost of contributor for Bx processÞ
 ðpresent cost of contributor for CM processÞÞ
=ðpresent cost of Bx processÞ ð4Þ
To clarify the above definition, note that
∑
ðcontributorsÞ
ðcontribution to present cost differenceÞ
¼ ðpercentage present cost difference vs batchÞ ð5Þ
’RESULTS
Capital Expenditures (CapEx). Process CM1 with direct
tablet formation has the largest CapEx savings (3176% savings
vs batch processing). At the highest KI price, the working capital,
especially for the KI, dominates CapEx, so savings are similar for
Table 5. Summary of OpEx Heuristics Used
item cost
(1) labor and supervision $160,000/year per operator;15 number of operators estimated as in Ulrich;16 twice as many
operators required for batch processes as for continuous
(2) materials handling and storage continuous is estimated at 40% of batch
(3) oﬀ-spec product 0% for batch and continuous
(4) quality assurance and control (QA/QC) continuous is estimated at 50% of batch
(5) utilities $1.50/kg material input
(6) waste disposal $2.50/gallon for water and organic solvents; $15.00/gallon for all other material17
(7) total OpEx sum of items (1) to (6) plus raw material costs
Table 6. CapEx (Including Working Capital) Diﬀerences for All Process Options, Relative to Batch Case, For Upstream and
Downstreama
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
Batch (basis for diﬀerences) Tot: [$315M] Tot: [$346M] Tot: [$542M] Tot: [$429M] Tot: [$585M] Tot: [$1565M]
U: [$73M] U: [$105M] U: [$300M] U: [$173M] U: [$329M] U: [$1308M]
D: [$242M] D: [$242M] D: [$242M] D: [$256M] D: [$256M] D: [$256M]
CM1R with direct tablet formation Tot: 28% Tot: 33% Tot: 54% Tot: 39% Tot: 53% Tot: 76%
U: 31% U: 49% U: 76% U: 52% U: 70% U: 85%
D: 27% D: 27% D: 27% D: 31% D: 31% D: 31%
CM1 with direct tablet formation Tot: 31% Tot: 36% Tot: 55% Tot: 42% Tot: 55% Tot: 76%
U: 43% U: 57% U: 78% U: 59% U: 73% U: 85%
D: 27% D: 27% D: 27% D: 31% D: 31% D: 31%
CM1R with roller compaction Tot: 20% Tot: 26% Tot: 49% Tot: 34% Tot: 49% Tot: 75%
U: 31% U: 49% U: 76% U: 52% U: 70% U: 85%
D: 17% D: 17% D: 17% D: 21% D: 21% D: 21%
CM1 with roller compaction Tot: 23% Tot: 29% Tot: 50% Tot: 36% Tot: 50% Tot: 74%
U: 43% U: 57% U: 78% U: 59% U: 73% U: 85%
D: 17% D: 17% D: 17% D: 21% D: 21% D: 21%
aAbbreviations: Tot,total CapEx; U, upstreamCapEx; D, downstreamCapEx. CapEx dollar amounts are provided in square brackets for the base case of
a batch process.
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all processes. Detailed results are given in Table 6; summarized
results are given in Table 7.
Operating Expenditures (OpEx). Process CM1R with either
direct tablet formation or roller compaction has the lowest
annual OpEx of any process option (640% savings); process
CM1 options show slightly less savings, due to the lower overall
yield without recycling. Detailed results are given in Table 8;
summarized results are given in Table 9.
Overall Cost of Production. Process CM1R with direct tablet
formation has the lowest present cost (940% savings). CM1R
with roller compaction is the next best option, with very similar
savings. See Table 10.
If the overall yield of process CM1R is 10% below that of the
batch process (Table 11), the overall costs of continuous
processing are between 4% higher and 35% lower than batch
processing if the best process is chosen for each API loading/KI
price scenario. At $3000/kg for the KI, all continuous processes
are estimated to be more expensive than the batch process. If the
overall yield is 10% higher for CM1R than for the batch process
(Table 12), 1935% savings can be achieved versus batch in all
low API loading cases by choosing process CM1R with direct
tablet formation.
Contributors to Overall Cost Savings. In Table 13, the
present cost of the project for the baseline case in which
CM1R yield is equal to batch yield is broken down into
contributions for each category (cf. eq 4). The values are for
the novel continuous process with recycling with direct tablet
formation (CM1R/DTF) and are similar to those for the other
novel CM options (not published).
The expenditures for the KI and for excipients are the same for
CM1R/DTF and batch, since equally priced excipients are used
and the overall yield of drug substance from KI is assumed equal
in CM1R and batch. The cost of the other organic reagents
needed in the novel continuous process are lower, reducing
OpEx in the “other” raw materials category. The novel contin-
uous process also has lower solvent usage, reducing costs of other
rawmaterials and waste handling. Moving toward higher KI price
in the table means the KI makes up a higher fraction of the
Table 7. Summary of CapEx Diﬀerences for All Process Options, Relative to Batch Casea
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
batch (basis for diﬀerences) [$315M] [$346M] [$542M] [$429M] [$585M] [$1565M]
CM1R with direct tablet formation 28% 33% 54% 39% 53% 76%
CM1 with direct tablet formation 31% 36% 55% 42% 55% 76%
CM1R with roller compaction 20% 26% 49% 34% 49% 75%
CM1 with roller compaction 23% 29% 50% 36% 50% 74%
aTotal CapEx dollar amounts are provided in square brackets for the base case of a batch process.
Table 8. Annual OpEx Diﬀerences for All Process Options, Relative to Batch Casea
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
Batch (basis for diﬀerences) Tot: [$136M] Tot: [$226M] Tot: [$785M] Tot: [$531M] Tot: [$979M] Tot: [$3777M]
URM: [$49M] URM: [$139M] URM: [$698M] URM: [$246M] URM: [$693M] URM: [$3491M]
DRM: [$25M] DRM: [$25M] DRM: [$25M] DRM: [$16M] DRM: [$16M] DRM: [$16M]
Oth: [$62M] Oth: [$62M] Oth: [$62M] Oth: [$269M] Oth: [$269M] Oth: [$269M]
CM1R with direct tablet formation Tot: 33% Tot: 20% Tot: 6% Tot: 40% Tot: 22% Tot: 6%
URM: 36% URM: 13% URM: 2% URM: 36% URM: 13% URM: 2%
DRM: 0% DRM: 0% DRM: 0% DRM: 1% DRM: 1% DRM: 1%
Oth: 45% Oth: 45% Oth: 45% Oth: 47% Oth: 47% Oth: 47%
CM1 with direct tablet formation Tot: 19% Tot: 6% Tot: 8% Tot: 22% Tot: 6% Tot: 9%
URM: 6% URM: 7% URM: 13% URM: 6% URM: 7% URM: 13%
DRM: 0% DRM: 0% DRM: 0% DRM: 1% DRM: 1% DRM: 1%
Oth: 36% Oth: 36% Oth: 36% Oth: 38% Oth: 38% Oth: 38%
CM1R with roller compaction Tot: 33% Tot: 20% Tot: 6% Tot: 40% Tot: 22% Tot: 6%
URM: 36% URM: 13% URM: 2% URM: 36% URM: 13% URM: 2%
DRM: 0% DRM: 0% DRM: 0% DRM: 1% DRM: 1% DRM: 1%
Oth: 45% Oth: 45% Oth: 45% Oth: 47% Oth: 47% Oth: 47%
CM1 with roller compaction Tot: 19% Tot: 6% Tot: 8% Tot: 22% Tot: 6% Tot: 9%
URM: 6% URM: 7% URM: 13% URM: 6% URM: 7% URM: 13%
DRM: 0% DRM: 0% DRM: 0% DRM: 1% DRM: 1% DRM: 1%
Oth: 36% Oth: 36% Oth: 36% Oth: 38% Oth: 38% Oth: 38%
aAbbreviations: Tot, total OpEx; URM, upstream raw materials OpEx; DRM, downstream raw materials OpEx; Oth, all other OpEx. OpEx dollar
amounts are provided in square brackets for the base case of a batch process.
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expenses, so percentage savings are reduced. However, the
working capital (in-process inventory) savings measured in
dollars are increased moving toward higher KI price, since the
batch process has 10 times more in-process inventory. For a
given KI price, the percentage savings due to working capital is
similar for high and low loadings. This may initially seem
counterintuitive since the high-loading processes require ﬁve
times more KI, the most expensive raw material. However, the
high-loading cases also have about four times greater overall cost
than the corresponding low-loading cases, so the percentage
savings are similar.
In the low API loading scenarios, the largest savings con-
sistently come from (ﬁrst) other raw materials, (second)
utilities, (third) waste handling, (fourth) CapEx excluding
working capital, (ﬁfth) labor and materials handling, (sixth)
QA/QC, and (seventh) other organic reagents. The signiﬁ-
cance of working capital varies depending on the KI price; it is
the ﬁrst, sixth, or eighth contributor to cost savings for KI
prices of $3000/kg, $500/kg, and $100/kg, respectively.
In the high API loading scenarios, the largest savings consis-
tently come from (ﬁrst) other raw materials, (second) utilities,
(third) labor and materials handling, (fourth) waste handling,
(ﬁfth) QA/QC, (sixth) other organic reagents, (seventh) CapEx
excluding working capital. The signiﬁcance of working capital
again depends on the KI price; it is the ﬁrst, ﬁfth, or seventh most
signiﬁcant contributor to cost savings for KI prices of $3000/kg,
$500/kg, and $100/kg, respectively.
’DISCUSSION
Batch and continuous production of a very large-scale pharma-
ceutical product produced in dedicated batch or continuous plants
was analyzed. This is one of the ﬁrst market segments in which
continuous pharmaceutical manufacturing may be implemented.
Overall cost savings of 9 to 40% are predicted if the appropriate
process is selected for the API loading/KI price scenario at hand.
The novel process with recycling (CM1R) with direct tablet
formation is consistently one of the most favorable processes, with
the same or slightly more savings than CM1 with roller compaction.
Percentage savings are greatest when KI prices are lower. This is
because the expenditure for the KI is the same in batch and CM1R,
that expenditure is proportional to KI price, and all other expenses
Table 9. Summary of Annual OpEx Diﬀerences for All Process Options, Relative to Batch Casea
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
batch (basis for diﬀerences) [$136M] [$226M] [$785M] [$531M] [$979M] [$3777M]
CM1R with direct tablet formation 33% 20% 6% 40% 22% 6%
CM1 with direct tablet formation 19% 6% 8% 22% 6% 9%
CM1R with roller compaction 33% 20% 6% 40% 22% 6%
CM1 with roller compaction 19% 6% 8% 22% 6% 9%
aAnnual OpEx dollar amounts are provided in square brackets for the base case of a batch process.
Table 10. Summary of Present Cost Diﬀerences for All Process Options, Relative to Batch Casea
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
batch (basis for diﬀerences) [$1515M] [$2337M] [$7472M] [$5117M] [$9225M] [$34902M]
CM1R with direct tablet formation 32% 22% 9% 40% 24% 9%
CM1 with direct tablet formation 21% 10% 4% 24% 9% 5%
CM1R with roller compaction 30% 21% 9% 40% 23% 9%
CM1 with roller compaction 20% 9% 4% 23% 8% 5%
a Present cost is the total discounted cost of the project, excluding any revenue, for the 15-year project lifetime. Present cost dollar amount is provided in
square brackets for the base case of a batch process.
Table 11. Summary of Present Cost Diﬀerences if CM1R Yield is 10% below Batch Yielda
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
batch (basis for diﬀerences) [$1515M] [$2337M] [$7472M] [$5117M] [$9225M] [$34902M]
CM1R with direct tablet formation 28% 15% 3% 35% 14% 4%
CM1 with direct tablet formation 16% 1% 18% 16% 3% 20%
CM1R with roller compaction 27% 13% 3% 34% 14% 4%
CM1 with roller compaction 14% 0% 18% 15% 3% 20%
a Present cost is the total discounted cost of the project, excluding any revenue, for the 15-year project lifetime. Present cost dollar amount is provided in
square brackets for the base case of a batch process.
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except working capital are insensitive to KI price. That is, as KI price
approaches inﬁnity, present cost savings approach the working
capital savings from the reduced in-process inventory.
The process development costs will tend to be greater for
continuous manufacturing processes as opposed to batch processes,
because the pharmaceutical industry has less experience with
continuous processing and the absence of conventional batches in
the highly regulated industry demands more process understanding
and online instrumentation (i.e., PAT). This was accounted for as a
10% price premium for continuous processing equipment at the
same scale as an equivalent batch process. With the current trend
toward smaller continuous processes (e.g., microreactors), however,
more process understanding will be obtained at early stages of the
process development, making scaleup easier and less expensive over
time. Furthermore, the smaller scale required for each unit in a
continuous process (due to greater eﬀective utilization time) usually
oﬀsets the additional process understanding and control required.
Some unit operations are easier to characterize in continuousmode:
Dhenge et al.18 claims that continuous granulation processes can be
developed more quickly, with associated savings in API material
during development. Once the process is operational, labor costs are
typically lower as well.
The capital expenditure for the novel direct tablet formation
process was based on a vendor quotation, but since it has not
been used in the pharmaceutical industry, the equipment cost is
subject to more uncertainty than most of the other costs. A
typical Wroth factor for the process under consideration in other
industries is about 2.0, but the standard value for “other equip-
ment” of 3.5 has been assumed (cf. Table 3). This assumption
allows for cost increases speciﬁc to the pharmaceutical industry
and may be unnecessarily high, meaning that the realized cost
savings for the direct tablet formation process may be greater
than those estimated here. The novel direct tablet formation
process should also be more broadly applicable than roller
compaction and eliminate other costs related to powder handling
that are not considered in this study. In addition to the direct
tablet formation approach reported here, we are developing
another novel tablet formation process (not yet published) that
should have signiﬁcantly better yields than roller compaction.
Although diﬀerent aspects of continuous pharmaceutical pro-
duction have been analyzed,1,8,9,12 no articles have been published
comparing the overall economics of batch and continuous phar-
maceutical processes producing drug product (tablets) from an
organic key intermediate. A presentation at the American Associa-
tion of Pharmaceutical Scientists meeting on Drug Product
Manufacturing claimed 58%CapEx savings and 67% annual OpEx
savings for a continuous pharmaceutical processing facility versus a
batch processing facility.19 A study on production of ethanol
Table 12. Summary of Present Cost Diﬀerences if CM1R Yield is 10% above Batch Yielda
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
batch (basis for diﬀerences) [$1515M] [$2337M] [$7472M] [$5117M] [$9225M] [$34902M]
CM1R with direct tablet formation 35% 28% 19% 44% 31% 19%
CM1 with direct tablet formation 25% 17% 7% 30% 18% 6%
CM1R with roller compaction 33% 27% 18% 44% 31% 19%
CM1 with roller compaction 24% 16% 7% 29% 17% 6%
a Present cost is the total discounted cost of the project, excluding any revenue, for the 15-year project lifetime. Present cost dollar amount is provided in
square brackets for the base case of a batch process.
Table 13. Contributions to Present Cost Diﬀerence Relative to Batch for Novel Continuous Process with Recycling (CM1R) with
Direct Tablet Formationa
API mass loading = 10% API mass loading = 50%
cost of KI : $100/kg $500/kg $3000/kg $100/kg $500/kg $3000/kg
organic reagents 2.2% 1.4% 0.4% 3.2% 1.8% 0.5%
KI 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
other raw materials 8.0% 5.2% 1.6% 11.9% 6.6% 1.7%
excipients 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
labor and materials handling 4.1% 2.6% 0.8% 5.3% 3.0% 0.8%
waste handling 4.4% 2.8% 0.9% 5.0% 2.8% 0.7%
utilities 4.7% 3.0% 0.9% 6.9% 3.8% 1.0%
QA/QC 2.9% 1.9% 0.6% 4.3% 2.4% 0.6%
CapEx excluding working capital 4.2% 2.7% 0.8% 1.6% 0.9% 0.2%
working capital/in-process inventory 1.6% 2.2% 3.1% 1.7% 2.5% 3.2%
total: 32% 22% 9% 40% 24% 9%
=[$485M] =[$513M] =[$689M] =[$2048M] =[$2188M] =[$3066M]
aDiﬀerence in present cost relative to batch case is provided in square brackets. Contribution to present cost diﬀerence relative to batch is deﬁned by eq
4. Since the continuous yield is identical to the batch yield, the contribution of KI cost to overall savings is identically zero in all cases.
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estimated 57%CapEx savings by shifting the process frombatch to
continuous mode.20 A study on production of cell culture media
estimated overall cost savings at 34% for switching from batch to
continuous production at 100 000 L/year capacity.21 A study on
production of ﬁne chemicals on dedicated batch versus continuous
equipment found that continuous production is economically
favorable at all production levels studied (as low as 200 t/year).22
Thus, this case study of a speciﬁc pharmaceutical product found
results similar to those found in other industries.
Some areas of continuous processing in pharmaceuticals are
well understood, whereas others require further study. Microreac-
tors and other continuous-ﬂow reactors have received quite a lot of
study;79,23,24 however, eﬃcient chemistry for the particular
product being produced is absolutely crucial. Particularly in the
case of high KI price, a 10% yield diﬀerence can shift a continuous
process from providing cost savings to providing cost increases
(see Tables 11 and 12). Continuous granulation processes have
also been widely studied.4,18,2530 On the contrary, studies on
continuous crystallization for pharmaceuticals has been lacking
until recently.31 The recent research is promising: one study found
that the puriﬁcation of an API using a continuous oscillatory
baﬄed crystallizer is muchmore predictable to scale up than batch
crystallization, as well as having a lower residence time: the
continuous process took 12 min as opposed to 9 h and 40 min
using the batch process.31 The easy scaleup in this type of
continuous crystallizer compares favorably with the 10 diﬀerent
schemes for scaling-up batch crystallization enumerated by
Lawton et al.3143 Despite recent promising results on continuous
crystallization of pharmaceuticals, appropriate solvents and con-
ditions must be chosen for each speciﬁc puriﬁcation step in each
particular manufacturing process. Other eﬀective separations
technologies may become more promising under continuous
mode as well.4447 Vervaet and Remon4 wrote a review article
on six diﬀerent methods of continuous granulation. The best-
studied method for continuous granulation is extrusion, on which
the ﬁrst papers for pharmaceutical applications were published in
1986,25 and much subsequent work has been completed.18,2630
Commercial equipment for creating the ﬁnal dosage form such as
continuous tableting and coating is already available; alternative
methods for doing so may prove even more eﬃcient.
Apart from considerations of continuous pharmaceutical
manufacturing unit operations, more economic analysis and
system-level research is also required, speciﬁcally, analysis of
smaller-scale production and the considerations of a multipur-
pose continuous production line rather than a line dedicated to a
single product. For example, how much time is needed to change
between products, and how much waste material is generated
during startup and shutdown, when the production line has not
reached steady state, as well as the economic implications there-
of. Plantwide dynamic models are essential for this task.48
’CONCLUSION
An integrated cost estimation of the production of a ﬁnal drug
product from a key organic intermediate was performed, using a
batch process and four continuous processes. To make the
analysis applicable to a wider range of products, the analysis
was performed with two API loading levels in the ﬁnal drug
product, three prices for the most expensive KI organic feed-
stock, three continuous API synthesis processes, and two con-
tinuous drug product formation processes. The overall cost of
production can be reduced most by changing to the continuous
process with recycling (CM1R) with the novel direct tablet
formation process in all scenarios tested if overall yields for the
continuous process meet or exceed those of the batch process; in
those two yield scenarios, the savings are 9 to 40% and 19 to 44%,
respectively. If the CM process with recycling has 10% lower
yield than the batch plant, savings can be achieved for all
scenarios except the highest KI price. The break-even KI price
is $1700/kg. Again, the maximal savings can be achieved by
choosing process CM1R with the novel direct tablet formation
process. When combining the economic advantage with more
consistent product quality and greater regulatory freedom, con-
tinuous manufacturing of pharmaceuticals is a viable way for the
pharmaceutical industry to achieve substantial cost savings.Many
opportunities for further study exist: developing more eﬃcient
chemical routes, separations technologies, ﬁnal dosage form
production, and plantwide modeling are all expected to lead to
more economical processes.
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